1175ODurvalumab activity in previously treated patients who stopped durvalumab without disease progression

ConclusionsThis is the largest cohort supporting the role of rechallenge with a PD-1/PD-L1 inhibitor in patients who have previously progressed after planned interruption. Rechallenge with durvalumab resulted in restored antitumor efficacy, high rates of disease control, and prolonged durability in patients who responded. These findings support the role of durvalumab in patients who progressed after planned treatment interruption.Clinical trial identificationNCT01693562.Legal entity responsible for the studyAstraZeneca, PLC.FundingAstraZeneca.DisclosureS. Sheth: Research grant / Funding (institution): AstraZeneca. C. Gao: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. N. Mueller: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. P. Martinez: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. J. Soria: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 20 January 2020Source: Trends in Food Science &TechnologyAuthor(s): Qiong-Qiong Yang, Arakkaveettil Kabeer Farha, Gowoon Kim, Khalid Gul, Ren-You Gan, Harold CorkeAbstractBackgroundCurcumin has gained increasing attention in recent years due to its biological properties and photosensitivity. Curcumin-mediated photodynamic therapy has been used in antibacterial and anticancer applications. Considering the importance and rapid advances in curcumin-mediated photodynamic treatments and its related beneficial functions, a comprehensive and up-to-date review is timely to summarize the state...
Source: Trends in Food Science and Technology - Category: Food Science Source Type: research
Publication date: Available online 20 January 2020Source: Trends in Food Science &TechnologyAuthor(s): Saikat Sen, Raja Chakraborty, Pratap KalitaAbstractBackgroundRice (Oryza sativa L.) is the most popular staple food grain and an important source of fibre, energy, minerals, vitamins, and other biomolecules. Rice parts exhibited a number of health beneficial effect in pre-clinical/clinical studies. Rice constituents are getting popularity in preparation of pharmaceutical adjuvant, food additives and supplements.Scope &approachIn this paper, we summarized the available literature on health-promoting and therapeutic...
Source: Trends in Food Science and Technology - Category: Food Science Source Type: research
Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions: In OSCC, very low preoperative NLR values have a negative prognostic impact on survival and recurrence, similarly to high ratios. ENE and perineural spread are the most important clinical-pathologic prognosticators. Introduction Oral squamous cell carcinoma (OSCC) accounts for more than 95% of oral tumors and is the eighth most frequent cancer worldwide, with an estimated incidence of 640,000 new cases per year (1). Survival of OSCC has slightly improved over the last 30 years, probably as a consequence of multimodal treatment spreading. However, intensified therapeutic regimens can result in signific...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, T cells deficient in TRAF6 display enhanced T cell activation, CD28-indpendent stimulation and resistance to Treg cell-mediated suppression (176). Although TLR signaling can promote T cell resistance to Treg cells, the precise molecular mechanism remains yet to be elucidated. It is worth noting that TLR stimulation of T cells increases cytokine production (173, 177), thus future studies should delineate the effect of TLR-MyD88 signaling vs. subsequently induced cytokines in generating resistance to Treg cells. Lastly, it is also crucial to evaluate the effect of TLR signaling on regulatory T cells which also...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Joe Abdo1, Christopher S. Wichman2, Nicholas E. Dietz1,3, Pawel Ciborowski4, John Fleegel1, Sumeet K. Mittal1,5 and Devendra K. Agrawal1* 1Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, United States 2Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States 3Department of Pathology, CHI Health Creighton University Medical Center, College of Medicine, Omaha, NE, United States 4Department of Pharmacology, University of Nebraska Medical Center, Omaha, NE, United States 5Norton Thoracic Institute, St....
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Ionescu DN, Downes MR, Christofides A, Tsao MS Abstract Checkpoint inhibitors targeting the programmed cell death 1 protein (PD-1) and programmed cell death ligand 1 (PD-L1) are demonstrating promising efficacy and appear to be well tolerated in a number of tumour types. In non-small-cell lung cancer, head-and-neck squamous cell carcinoma, and urothelial carcinoma, outcomes appear particularly favourable in patients with high PD-L1 expression. However, assays for PD-L1 have been developed for individual agents, and they use different antibody clones, immunohistochemistry staining protocols, scoring algorit...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
AbstractOver the last two decades, molecular-targeted agents have become mainstream treatment for many types of malignancies and have improved the overall survival of patients. However, most patients eventually develop resistance to these targeted therapies. Recently, immunotherapies such as immune checkpoint inhibitors have revolutionized the treatment paradigm for many types of malignancies. Immune checkpoint inhibitors have been approved for treatment of melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, Hodgkin ’s lymphoma, bladder cancer and gastric cancer. However...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Date: January 1, 2018 Issue #:  1537Summary:  The immune checkpoint inhibitor pembrolizumab (Keytruda– Merck), a programmed death receptor-1 (PD-1) inhibitor, has been granted accelerated approval by the FDA for use in adults and children who have unresectable or metastatic microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) solid tumors that have progressed following trea tment, and do not have any satisfactory alternative treatment options. For metastatic colorectal cancer, the indication is limited to tumors that have progressed following combination treatment w...
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research
Learning Module - In this text module and accompanying downloadable slideset, experts review key study results presented at the 2017 ESMO annual meeting across multiple malignancies including advanced NSCLC, breast cancer, bladder cancer, renal cell carcinoma, gastric/gastroesophageal cancer, HNSCC, and hepatocellular carcinoma.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research
More News: AstraZeneca | Bladder Cancer | Cancer | Cancer & Oncology | Clinical Trials | Employment | Funding | Grants | HNSCC | Legislation | Non-Small Cell Lung Cancer | Study